替吉奥胶囊联合注射用奥沙利铂治疗进展期胃癌临床疗效和安全性分析

S-1 Combined with Oxaliplatin for Injection Treatment of Clinical Efficacy and Safety of Advanced Gastric Cancer

目的探讨替吉奥胶囊与奥沙利铂联合对胃癌患者治疗效果分析。方法选择该院药剂科2014年1—10月收治的58例胃癌患者为观察组,采取奥沙利铂及替吉奥胶囊联合治疗,另选同期收治的32例实施奥沙利铂、卡培他滨联合治疗患者为对照组,经治疗后,对比两组疗效及CD4+、CD4+/CD8+水平变化情况。结果观察组治疗总有效率为74.14%,对照组为50.00%,观察组明显高于对照组(P<0.05);治疗后观察组CD4+为(38.87±4.72)、CD4+/CD8+(1.54±0.31)相较于对照组差异有统计学意义,P<0.05。结论奥沙利铂及替吉奥胶囊联合对进展期胃癌治疗效果满意,且安全性较高,减少毒性反应及胃肠道反应,患者耐受性较好,利于患者预后,但是该组探究病例数较少,可能与其他研究所得数据有所偏差,还有待更多大型前瞻性研究对其疗效进行验证。

Objective Explore for tegafur capsule and oxaliplatin into joint analysis of treatment effect in patients with gastric cancer.Methods Choose our hospital pharmacy department between January 2014 and October, 2014, 58 patients with gastric cancer as the observation group, adopt and oxaliplatin into capsule combined treatment for tegafur,swap over the same period of 32 cases of oxaliplatin into and capecitabine combination therapy for patients with the control group, after treatment, compared two groups of curative effect and CD4 +, CD4 + / CD8 + level changes. Results The observation group treatment the total effective rate was 74.14%, control group was 50.00%, the observation group is significantly higher than control group(P < 0.05); Observation group after treatment for CD4 +(38.87± 4.72),CD4 + / CD8 +(1.54±0.31) significant difference compared with control group, P < 0.05. Conclusion And oxaliplatin into for tegafur capsule for the treatment of advanced gastric cancer effect is satisfied, and high safety, less toxic reaction and gastrointestinal reaction, the patient has good tolerance, good for patients prognosis, but the number of cases is less, this inquiry may be related to the data from other studies have deviation, it remains to be more large prospective studies to validate their effectiveness.